BACKGROUND: Prostate cancer (PCa) outcomes are impacted by socioeconomic and biologic factors. Ethnicity plays a role in the former, but little is known about the responsiveness of metastatic PCa to androgen-deprivation therapy (ADT) among races. METHODS: The Surveillance, Epidemiology, and End Results (SEER) registry was used to identify men who were diagnosed with distant, de novo, metastatic PCa from 2004 to 2012. Patterns of presentation, overall survival (OS), and PCa-specific mortality (PCSM) were determined for each race. E3805 clinical trial data also were retrospectively reviewed to assess outcomes of ADT and ADT plus docetaxel by race. RESULTS: Of all PCa diagnoses in SEER, distant, de novo, metastatic disease was diagnosed in 4.2% of non-Hispanic whites, 5.8% of Hispanic whites, 5.7% of blacks, 5.5% of Asians/Pacific Islanders, and 8.8% of American Indians/Alaska Natives (P < .001; chi-square test). The median OS differed by race, with superior OS observed among Asian men (30 months) than among men of other races (range, 24-25 months; P < .001). Asians also had a superior median PCSM (54 months) compared with the other races (range, 35-40 months; P < .001). In E3805, chemohormonal therapy was associated with a median OS of 58.1 months (95% confidence interval, 48.8-72.9 months) and 57.6 months (95% confidence interval, 27.7-57.6 months) in non-Hispanic whites and blacks, respectively. Few Asians participated in the E3805 trial. CONCLUSIONS: Asian men have superior median OS and PCSM for distant, de novo, metastatic PCa than men of other race. Non-Hispanic whites and blacks who receive treatment with ADT or chemohormonal therapy have comparable outcomes. Cancer 2017;123:1536-1544.
BACKGROUND:Prostate cancer (PCa) outcomes are impacted by socioeconomic and biologic factors. Ethnicity plays a role in the former, but little is known about the responsiveness of metastatic PCa to androgen-deprivation therapy (ADT) among races. METHODS: The Surveillance, Epidemiology, and End Results (SEER) registry was used to identify men who were diagnosed with distant, de novo, metastatic PCa from 2004 to 2012. Patterns of presentation, overall survival (OS), and PCa-specific mortality (PCSM) were determined for each race. E3805 clinical trial data also were retrospectively reviewed to assess outcomes of ADT and ADT plus docetaxel by race. RESULTS: Of all PCa diagnoses in SEER, distant, de novo, metastatic disease was diagnosed in 4.2% of non-Hispanic whites, 5.8% of Hispanic whites, 5.7% of blacks, 5.5% of Asians/Pacific Islanders, and 8.8% of American Indians/Alaska Natives (P < .001; chi-square test). The median OS differed by race, with superior OS observed among Asian men (30 months) than among men of other races (range, 24-25 months; P < .001). Asians also had a superior median PCSM (54 months) compared with the other races (range, 35-40 months; P < .001). In E3805, chemohormonal therapy was associated with a median OS of 58.1 months (95% confidence interval, 48.8-72.9 months) and 57.6 months (95% confidence interval, 27.7-57.6 months) in non-Hispanic whites and blacks, respectively. Few Asians participated in the E3805 trial. CONCLUSIONS: Asian men have superior median OS and PCSM for distant, de novo, metastatic PCa than men of other race. Non-Hispanic whites and blacks who receive treatment with ADT or chemohormonal therapy have comparable outcomes. Cancer 2017;123:1536-1544.
Authors: Sin Eng Chia; Chuen Seng Tan; Gek Hsiang Lim; Xueling Sim; Weber Lau; Kee Seng Chia Journal: Ann Acad Med Singapore Date: 2010-06 Impact factor: 2.473
Authors: Heidi A Hanson; Christopher Martin; Brock O'Neil; Claire L Leiser; Erik N Mayer; Ken R Smith; William T Lowrance Journal: J Urol Date: 2019-06-27 Impact factor: 7.450
Authors: Camilo Arenas-Gallo; Jude Owiredu; Ilon Weinstein; Patrick Lewicki; Spyridon P Basourakos; Randy Vince; Bashir Al Hussein Al Awamlh; Fredrick R Schumacher; Daniel E Spratt; Christopher E Barbieri; Jonathan E Shoag Journal: Nat Rev Urol Date: 2022-08-09 Impact factor: 16.430
Authors: Arsheed A Ganaie; Firdous H Beigh; Matteo Astone; Marina G Ferrari; Raihana Maqbool; Syed Umbreen; Aijaz S Parray; Hifzur R Siddique; Tabish Hussain; Paari Murugan; Colm Morrissey; Shahriar Koochekpour; Yibin Deng; Badrinath R Konety; Luke H Hoeppner; Mohammad Saleem Journal: Clin Cancer Res Date: 2018-08-07 Impact factor: 12.531
Authors: Victoria Wang; Milan S Geybels; Kristina M Jordahl; Travis Gerke; Anis Hamid; Kathryn L Penney; Sarah C Markt; Matthew Freedman; Mark Pomerantz; Gwo-Shu M Lee; Huma Rana; Daniela Börnigen; Timothy R Rebbeck; Curtis Huttenhower; Ros A Eeles; Janet L Stanford; Practical Consortium; Sonja I Berndt; Frank Claessens; Karina D Sørensen; Jong Y Park; Ana Vega; Nawaid Usmani; Lorelei Mucci; Christopher J Sweeney Journal: Prostate Date: 2021-05-06 Impact factor: 4.012
Authors: Benedikt Hoeh; Jan L Hohenhorst; Rocco Flammia; Benedikt Horlemann; Gabriele Sorce; Francesco Chierigo; Zhe Tian; Fred Saad; Markus Graefen; Michele Gallucci; Alberto Briganti; Carlo Terrone; Shahrokh F Shariat; Luis A Kluth; Andreas Becker; Felix K H Chun; Pierre I Karakiewicz Journal: Int Urol Nephrol Date: 2021-11-16 Impact factor: 2.370